Aquatic Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Aquatic Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.63M	Buy	43,743 +38,613	+753%	+$1.25M	0.06%	421
2026 Q1	$163K	Buy	+5,130	New	+$140K	﹤0.01%	1026
2025 Q3	–	Sell	-23,965	Closed	-$488K	–	1422
2025 Q2	$488K	Buy	23,965 +12,989	+118%	+$253K	0.01%	828
2025 Q1	$199K	Buy	10,976 +6,196	+130%	+$138K	0.01%	934
2024 Q4	$121K	Buy	+4,780	New	+$130K	﹤0.01%	1035
2024 Q2	–	Sell	-4,100	Closed	-$172K	–	1284
2024 Q1	$172K	Buy	4,100 +700	+21%	+$28.7K	0.01%	800
2023 Q4	$135K	Buy	+3,400	New	+$100K	﹤0.01%	941
2023 Q2	–	Sell	-14,900	Closed	-$536K	–	1387
2023 Q1	$536K	Buy	+14,900	New	+$643K	0.03%	399
2022 Q4	–	Sell	-15,500	Closed	-$436K	–	1427
2022 Q3	$436K	Buy	+15,500	New	+$475K	0.04%	442

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aquatic Capital Management's CLDX Position: Q2 2026 in Review

Aquatic Capital Management increased its Celldex Therapeutics (CLDX) stake by 753% in Q2 2026, buying an estimated $1.25M and bringing the position to 43,743 shares worth $1.63M. The position accounts for 0.06% of the portfolio, ranked #421.

Aquatic Capital Management first reported a position in CLDX in Q3 2022 and has held it in 9 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Aquatic Capital Management held 43,743 shares of Celldex Therapeutics worth $1.63M as of Q2 2026.
Aquatic Capital Management bought 38,613 Celldex Therapeutics shares in Q2 2026, an estimated $1.25M.
Celldex Therapeutics made up 0.06% of Aquatic Capital Management's portfolio in Q2 2026, its #421 holding.
Aquatic Capital Management first reported a position in Celldex Therapeutics in Q3 2022 and has held it in 9 quarters since.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.